Integer Holdings Co. (NYSE:ITGR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Integer Holdings Co. (NYSE:ITGR) has been given an average rating of “Moderate Buy” by the nine analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $145.44.

ITGR has been the topic of a number of research analyst reports. Bank of America boosted their price target on shares of Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. KeyCorp increased their target price on shares of Integer from $139.00 to $144.00 and gave the company an “overweight” rating in a research report on Tuesday, October 15th. Citigroup upped their price objective on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. Piper Sandler reissued an “overweight” rating and issued a $140.00 target price (up from $125.00) on shares of Integer in a research report on Friday, October 25th. Finally, Truist Financial increased their price target on Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th.

Hedge Funds Weigh In On Integer

A number of institutional investors have recently added to or reduced their stakes in ITGR. Loomis Sayles & Co. L P lifted its stake in Integer by 3.0% during the third quarter. Loomis Sayles & Co. L P now owns 538,027 shares of the medical equipment provider’s stock worth $69,943,000 after purchasing an additional 15,446 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Integer by 23.3% in the 3rd quarter. Jane Street Group LLC now owns 151,397 shares of the medical equipment provider’s stock valued at $19,682,000 after purchasing an additional 28,572 shares in the last quarter. Earnest Partners LLC grew its holdings in shares of Integer by 3.2% during the 2nd quarter. Earnest Partners LLC now owns 1,208,319 shares of the medical equipment provider’s stock valued at $139,911,000 after purchasing an additional 37,340 shares during the last quarter. Verition Fund Management LLC raised its position in Integer by 17.4% in the 3rd quarter. Verition Fund Management LLC now owns 3,470 shares of the medical equipment provider’s stock worth $451,000 after purchasing an additional 515 shares during the period. Finally, Versant Capital Management Inc lifted its stake in Integer by 98.4% in the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock worth $49,000 after purchasing an additional 183 shares during the last quarter. 99.29% of the stock is currently owned by institutional investors.

Integer Stock Up 0.3 %

ITGR stock opened at $140.91 on Tuesday. The firm has a market capitalization of $4.73 billion, a PE ratio of 43.49, a P/E/G ratio of 1.70 and a beta of 1.12. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. Integer has a twelve month low of $94.56 and a twelve month high of $142.76. The stock’s 50 day moving average is $136.53 and its 200-day moving average is $128.87.

Integer (NYSE:ITGR) last posted its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.07. Integer had a net margin of 6.70% and a return on equity of 11.63%. The firm had revenue of $431.42 million for the quarter, compared to the consensus estimate of $440.59 million. During the same period in the previous year, the firm earned $1.27 EPS. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. Sell-side analysts expect that Integer will post 5.33 EPS for the current fiscal year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.